HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Will Cosmeceutical Pioneer Turn Its Wagons Around? FDA Warns Strivectin

This article was originally published in The Rose Sheet

Executive Summary

FDA cites Strivectin’s Potent Wrinkle Reducing Treatment and TL Advanced Tightening Neck Cream as unapproved drugs based on claims touting elastin-stimulating effects, skin-firming action and other structure/function benefits. Widely credited as a pioneer that helped create the cosmeceutical category, Strivectin has been warning-free since 2005 when FDA came down on its “Better than Botox?” positioning.

You may also be interested in...

FDA Warning Letter Recipients: Where Are Their Claims Now?

A key component of FDA’s enforcement strategy in the cosmetics space is monitoring companies’ websites for overreaching product claims and issuing warning letters accordingly. Examination of past offenders’ current sites and updated claims offers potential visibility into language the agency will and will not tolerate when it comes to promoting skin-care benefits.

People In Brief: IFRA NA's CEO Search Lands On PCPC Exec; More

Formerly assistant general counsel and currently chair of strategic industry categories at the Personal Care Products Council, Farah Ahmed will start as CEO of the International Fragrance Association North America April 18. More people news in brief.

2015 In Review: Tension Builds At The Regulatory Cosmetic/Drug Divide

FDA continued its crackdown on overreaching cosmetic claims in 2015, issuing nine warnings to cosmetic product marketers, while a draft bill emerged in the US House that would redefine "cosmetic" under federal law to provide companies with greater flexibility. Microbead legislation commanded the most national attention, with President Obama signing the federal Microbead-Free Waters Act to close out the year.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts